<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3301523</article-id><article-id pub-id-type="publisher-id">cc1967</article-id><article-id pub-id-type="doi">10.1186/cc1967</article-id><article-categories><subj-group subj-group-type="heading"><subject>Meeting Abstract</subject></subj-group></article-categories><title-group><article-title>Effects of citicoline treatment in patients with isolated head trauma: a randomized trial</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Lazowski</surname><given-names>T</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Kierul</surname><given-names>K</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Bartnicki</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Mayzner-Zawadzka</surname><given-names>E</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Toczylowska</surname><given-names>B</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Ryba</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Lewandowski</surname><given-names>Z</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib></contrib-group><aff id="I1"><label>1</label>II Department of Anaesthesiology and Intensive Care, Warsaw Medical School, Poland</aff><aff id="I2"><label>2</label>I Department of Anaesthesiology and Intensive Care, Warsaw Medical School, Poland</aff><aff id="I3"><label>3</label>Department of Epidemiology, Warsaw Medical School, Poland</aff><aff id="I4"><label>4</label>Institute of Biocybernetics and Biomedical Engineering of the Polish Academy of Sciences, Poland</aff><aff id="I5"><label>5</label>Laboratory of Experimental Pharmacology, Medical Research Centre of the Polish Academy of Sciences, Poland</aff><pub-date pub-type="ppub"><year>2003</year></pub-date><pub-date pub-type="epub"><day>3</day><month>3</month><year>2003</year></pub-date><volume>7</volume><issue>Suppl 2</issue><supplement><named-content content-type="supplement-title">23rd International Symposium on Intensive Care and Emergency Medicine</named-content></supplement><fpage>P078</fpage><lpage>P078</lpage><conference><conf-date>18-21 March 2003</conf-date><conf-name>23rd International Symposium on Intensive Care and Emergency Medicine</conf-name><conf-loc>Brussels, Belgium</conf-loc></conference></article-meta></front><body><sec><title>Background and goal of study</title><p>CDP Choline (CDPC, citicoline) is one of the neuroprotectants used for the clinical and experimental treatment of stroke [<xref ref-type="bibr" rid="B1">1</xref>] and brain injury [<xref ref-type="bibr" rid="B2">2</xref>]. In the present study the authors examined the effect of citicholine treatment on survival and neurological outcome in patients with brain injury caused by isolated head trauma.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>The study was approved by the institution ethical comity. Twenty-eight patients after head trauma (23 men) were randomly enrolled to typical treatment + citicholine (1 g IV for 14 days) group or typical treatment + placebo group. Glasgow Coma and Glasgow Outcome Scale (GCS, GOS) were used to monitor patients up to 30 days.</p></sec><sec><title>Results and discussions</title><p>Our preliminary report of the citicoline-treated group shows no correlation between GCS in day 7 (GCS 7) and day 14 (GCS 14). This lack of correlation is interpreted as a result of treatment, and significant correlation between GCS 14 and GCS 21 (<italic>r</italic> = 0.82; <italic>P</italic> &#x0003c; 0.007) is interpreted as an expanded effect of treatment to 21 days. In the citicoline group, GCS 21 is significantly correlated with GOS 30 (<italic>r</italic> = 0.68; <italic>P</italic> &#x0003c; 0.01) showing the protective effect of the used drug.</p><table-wrap id="T1" position="float"><label>Table 1</label><table frame="hsides" rules="groups"><thead><tr><th align="left">Variable</th><th align="center"><italic>n</italic></th><th align="center">Mean</th><th align="center">Standard deviation</th><th align="center">Median</th><th align="center">Minimum</th><th align="center">Maximum</th></tr></thead><tbody><tr><td align="left">GCS 0</td><td align="center">14</td><td align="center">6.00000</td><td align="center">1.10940</td><td align="center">6.00000</td><td align="center">4.00000</td><td align="center">8.00000</td></tr><tr><td align="left">GCS 1</td><td align="center">13</td><td align="center">6.03846</td><td align="center">1.19829</td><td align="center">6.00000</td><td align="center">4.00000</td><td align="center">8.00000</td></tr><tr><td align="left">GCS 7</td><td align="center">11</td><td align="center">7.13636</td><td align="center">2.12239</td><td align="center">6.00000</td><td align="center">4.00000</td><td align="center">10.00000</td></tr><tr><td align="left">GCS 14</td><td align="center">10</td><td align="center">9.35000</td><td align="center">2.62520</td><td align="center">9.50000</td><td align="center">4.00000</td><td align="center">13.00000</td></tr><tr><td align="left">GCS 21</td><td align="center">9</td><td align="center">11.33333</td><td align="center">3.67423</td><td align="center">13.00000</td><td align="center">4.00000</td><td align="center">15.00000</td></tr><tr><td align="left">GCS 30</td><td align="center">8</td><td align="center">12.50000</td><td align="center">2.77746</td><td align="center">13.50000</td><td align="center">8.00000</td><td align="center">15.00000</td></tr><tr><td align="left">GOS 30</td><td align="center">14</td><td align="center">2.42857</td><td align="center">1.55486</td><td align="center">2.00000</td><td align="center">1.00000</td><td align="center">5.00000</td></tr></tbody></table></table-wrap></sec><sec><title>Conclusions</title><p>Our preliminary results suggest that CDPC can be an effective neuroprotective agent in patients with brain injuries following head trauma. Our study has to and will be continued to confirm our data.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="book"><name><surname>Sandage</surname><given-names>BW</given-names></name><person-group person-group-type="editor">Savage LM</person-group><article-title>Citicoline: neural protection and repair.</article-title><source>Ischemic Stroke II</source><year>1996</year><publisher-name>Southborough, MA: International Business Communications, Inc</publisher-name><fpage>210</fpage><lpage>224</lpage></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="other"><name><surname>Baskaya</surname><given-names>MK</given-names></name><name><surname>Dogan</surname><given-names>A</given-names></name><name><surname>Rao</surname><given-names>AM</given-names></name><source>J Neurosurg</source><year>2000</year><volume>92</volume><fpage>448</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">10701532</pub-id></mixed-citation></ref></ref-list></back></article>